Johnson & Johnson vs. Sarepta Therapeutics,, Inc. Common Stock
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| JNJ | SRPT | |
|---|---|---|
| Market Cap | $628.65 billion | $1.94 billion |
| Revenue (TTM) | $97.93 billion | $1.97 billion |
| Net Income (TTM) | $21.04 billion | $-136,725,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | SRPT | |
|---|---|---|
| P/E Ratio | 30.20 | — |
| Price / Book | 7.40 | 1.27 |
| Price / Sales | 6.42 | 0.98 |
SRPT leads on 2 of 2 valuation factors.
Profitability
| JNJ | SRPT | |
|---|---|---|
| Net Margin | 21.48% | -6.93% |
| Return on Equity | 24.76% | -8.95% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | SRPT | |
|---|---|---|
| Dividend Yield | 2.06% | — |
| Payout Ratio | 62.18 | — |
JNJ and SRPT split the dividend factors evenly.
Risk & Sentiment
| JNJ | SRPT | |
|---|---|---|
| Short Interest | 0.67% | 9.38% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, SRPT overview, SRPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.